179 related articles for article (PubMed ID: 12007954)
21. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma.
Schenkein DP; Roitman D; Miller KB; Morelli J; Stadtmauer E; Pecora AL; Cassileth P; Fernandez H; Cooper BW; Kutteh L; Lazarus HM
Biol Blood Marrow Transplant; 1997 Oct; 3(4):210-6. PubMed ID: 9360783
[TBL] [Abstract][Full Text] [Related]
22. Autologous peripheral blood stem cell transplantation after high dose therapy in patients with advanced lymphomas.
Brice P; Marolleau JP; Dombret H; Lepage E; Baruchel A; Adam M; Miclea JM; Sitthy X; Gisselbrecht C
Bone Marrow Transplant; 1992 May; 9(5):337-42. PubMed ID: 1352162
[TBL] [Abstract][Full Text] [Related]
23. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
[TBL] [Abstract][Full Text] [Related]
24. CD34+-selected autologous peripheral blood stem cell transplantation conditioned with total body irradiation for malignant lymphoma: increased risk of infectious complications.
Maeda S; Kagami Y; Ogura M; Taji H; Suzuki R; Kondo E; Asakura S; Takeuchi T; Miura K; Ando M; Nakamura S; Ito T; Kinoshita T; Ueda R; Morishima Y
Int J Hematol; 2001 Aug; 74(2):214-21. PubMed ID: 11594525
[TBL] [Abstract][Full Text] [Related]
25. [Clinical analysis of autologous peripheral blood stem cell transplantation in 182 patients with non-Hodgkin's lymphoma].
Liu K; Lu D
Zhonghua Nei Ke Za Zhi; 2002 Jun; 41(6):363-6. PubMed ID: 12137594
[TBL] [Abstract][Full Text] [Related]
26. Treatment of refractory lymphoma with high dose cytarabine, cyclophosphamide and either TBI or VP-16 followed by autologous bone marrow transplantation.
Broun ER; Tricot G; Akard L; Nichols C; Cheerva A; Jansen J
Bone Marrow Transplant; 1990 May; 5(5):341-4. PubMed ID: 2190660
[TBL] [Abstract][Full Text] [Related]
27. Primary amyloidosis patients with significant organ dysfunction tolerate autologous transplantation after conditioning with single-dose total body irradiation alone: a feasibility study.
Blum W; Khoury H; Lin HS; Vij R; Goodnough LT; Devine S; Dipersio J; Adkins D
Biol Blood Marrow Transplant; 2003 Jun; 9(6):397-404. PubMed ID: 12813448
[TBL] [Abstract][Full Text] [Related]
28. Comparison of two total body irradiation fractionation regimens with respect to acute and late pulmonary toxicity.
Gopal R; Ha CS; Tucker SL; Khouri IF; Giralt SA; Gajewski JL; Andersson BS; Cox JD; Champlin RE
Cancer; 2001 Oct; 92(7):1949-58. PubMed ID: 11745270
[TBL] [Abstract][Full Text] [Related]
29. [A multicenter early phase II study of high-dose chemotherapy with autologous peripheral blood stem cell transplantation for treatment of intermediate-grade non-Hodgkin's lymphoma. Japan Blood Cell Transplantation Study Group].
Chou T; Ishiguro T; Imajo K; Kawano F; Gondo H; Kasai M; Masuda M; Koike M; Shimazaki C; Hara M; Shinagawa K; Ogawa M; Takaku F; Harada M
Rinsho Ketsueki; 1999 Oct; 40(10):1058-67. PubMed ID: 10565222
[TBL] [Abstract][Full Text] [Related]
30. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
Wheeler C; Khurshid A; Ibrahim J; Elias A; Mauch P; Ault K; Antin J
Leuk Lymphoma; 2001 Feb; 40(5-6):499-509. PubMed ID: 11426523
[TBL] [Abstract][Full Text] [Related]
31. Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease. a prospective randomised trial.
van Agthoven M; Vellenga E; Fibbe WE; Kingma T; Uyl-de Groot CA
Eur J Cancer; 2001 Sep; 37(14):1781-9. PubMed ID: 11549432
[TBL] [Abstract][Full Text] [Related]
32. A dose escalation study of total body irradiation followed by high-dose etoposide and allogeneic blood stem cell transplantation for the treatment of advanced hematologic malignancies.
Sobecks RM; Daugherty CK; Hallahan DE; Laport GF; Wagner ND; Larson RA
Bone Marrow Transplant; 2000 Apr; 25(8):807-13. PubMed ID: 10808200
[TBL] [Abstract][Full Text] [Related]
33. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma -- a retrospective evaluation.
Demirer T; Ayli M; Fen T; Ozcan M; Arat M; Buyukberber S; Arslan O; Gurman G; Akan H; Ilhan O
Bone Marrow Transplant; 2004 Nov; 34(9):781-6. PubMed ID: 15354206
[TBL] [Abstract][Full Text] [Related]
34. Tandem transplant of peripheral blood stem cells for patients with poor-prognosis Hodgkins's disease or non-Hodgkin's lymphoma.
Fitoussi O; Simon D; Brice P; Makke J; Scrobohaci ML; Bibi Triki T; Hennequin C; Fermé C; Gisselbrecht C
Bone Marrow Transplant; 1999 Oct; 24(7):747-55. PubMed ID: 10516678
[TBL] [Abstract][Full Text] [Related]
35. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W
Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
[TBL] [Abstract][Full Text] [Related]
36. Significance of molecular marker-positive cells after autologous peripheral-blood stem-cell transplantation for non-Hodgkin's lymphoma.
Hardingham JE; Kotasek D; Sage RE; Gooley LT; Mi JX; Dobrovic A; Norman JE; Bolton AE; Dale BM
J Clin Oncol; 1995 May; 13(5):1073-9. PubMed ID: 7738613
[TBL] [Abstract][Full Text] [Related]
37. Single dose or fractionated total body irradiation and autologous marrow transplantation in dogs: effects of exposure rate, fraction size, and fractionation interval on acute and delayed toxicity.
Deeg HJ; Storb R; Longton G; Graham TC; Shulman HM; Appelbaum F; Thomas ED
Int J Radiat Oncol Biol Phys; 1988 Sep; 15(3):647-53. PubMed ID: 3047091
[TBL] [Abstract][Full Text] [Related]
38. Prospective evaluation of pulmonary function in cancer patients treated with total body irradiation, high-dose melphalan, and autologous hematopoietic stem cell transplantation.
Gandola L; Siena S; Bregni M; Sverzellati E; Piotti P; Stucchi C; Gianni AM; Lombardi F
Int J Radiat Oncol Biol Phys; 1990 Sep; 19(3):743-9. PubMed ID: 1976614
[TBL] [Abstract][Full Text] [Related]
39. Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study.
Moreau P; Milpied N; Voillat L; Colombat P; Mahé B; Rapp MJ; Moreau A; Dupas B; Bulabois CE; Juge-Morineau N; Harousseau JL
Bone Marrow Transplant; 1998 Jun; 21(12):1193-6. PubMed ID: 9674850
[TBL] [Abstract][Full Text] [Related]
40. A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma.
Srivastava S; Jones D; Wood LL; Schwartz JE; Nelson RP; Abonour R; Secrest A; Cox E; Baute J; Sullivan C; Kane K; Robertson MJ; Farag SS
Biol Blood Marrow Transplant; 2011 Jul; 17(7):987-94. PubMed ID: 20965266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
